Have a feature idea you'd love to see implemented?
Let us know!
APGE Apogee Therapeutics Inc.
Price (delayed)
$47.71
Market cap
$2.79B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.42
Enterprise value
$2.69B
We are a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with
Highlights
APGE's equity has surged by 79% year-on-year but it is down by 5% since the previous quarter
The company's EPS has surged by 59% YoY but it fell by 17% QoQ
The debt has soared by 197% from the previous quarter
APGE's net income has dropped by 121% year-on-year and by 24% since the previous quarter
Key stats
What are the main financial stats of APGE
Market
Valuations
Earnings
Shares outstanding
58.51M
Market cap
$2.79B
Enterprise value
$2.69B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.8
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$146.66M
EBIT
-$146.66M
EBITDA
-$145.53M
Free cash flow
-$134.53M
Per share
Balance sheet
Liquidity
EPS
-$2.42
EPS diluted
-$2.42
Free cash flow per share
-$2.37
Book value per share
$12.56
Revenue per share
$0
TBVPS
$13.67
Total assets
$776.29M
Total liabilities
$41.88M
Debt
$12.14M
Equity
$734.4M
Working capital
$501.87M
Debt to equity
0.02
Current ratio
16.39
Quick ratio
16.13
Net debt/EBITDA
0.73
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-20.9%
Return on equity
-21.8%
Return on invested capital
-34.7%
Return on capital employed
-19.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
APGE stock price
How has the Apogee Therapeutics stock price performed over time
Intraday
0.82%
1 week
1.47%
1 month
8.53%
1 year
53.56%
YTD
70.76%
QTD
-18.78%
Financial performance
How have Apogee Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$178.14M
Net income
-$146.66M
Gross margin
N/A
Net margin
N/A
Apogee Therapeutics's operating income has shrunk by 155% YoY and by 24% QoQ
APGE's net income has dropped by 121% year-on-year and by 24% since the previous quarter
Growth
What is Apogee Therapeutics's growth rate over time
Valuation
What is Apogee Therapeutics stock price valuation
P/E
N/A
P/B
3.8
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 59% YoY but it fell by 17% QoQ
APGE's equity has surged by 79% year-on-year but it is down by 5% since the previous quarter
APGE's P/B is 3.3% below its last 4 quarters average of 3.9
Efficiency
How efficient is Apogee Therapeutics business performance
APGE's return on equity has surged by 78% year-on-year but it is down by 9% since the previous quarter
The company's return on invested capital has surged by 75% YoY and by 6% QoQ
Apogee Therapeutics's ROA has increased by 33% YoY but it has decreased by 8% from the previous quarter
Dividends
What is APGE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for APGE.
Financial health
How did Apogee Therapeutics financials performed over time
Apogee Therapeutics's total liabilities has surged by 144% YoY and by 55% QoQ
APGE's total assets has surged by 82% year-on-year but it is down by 3% since the previous quarter
The debt is 98% less than the equity
The debt has soared by 197% from the previous quarter
APGE's debt to equity has soared by 100% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.